Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2018

  • ID: 4464940
  • Report
  • 48 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 3-V Biosciences Inc
  • Biotron Ltd
  • CEL-SCI Corp
  • GeneCure LLC
  • Gilead Sciences Inc
  • Novavax Inc
  • MORE
Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2018, provides an overview of the Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline landscape.

Severe acute respiratory syndrome (SARS) is a serious, potentially life-threatening viral infection caused by virus from the Coronaviridae family. Symptoms include cough, chills and shaking, headache, muscle aches, diarrhea, dizziness, nausea and vomiting. Risk factors include gene variation in the immune system and close contact with someone who has SARS.

Report Highlights

The Publisher's Pharmaceutical and Healthcare latest pipeline guide Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Severe Acute Respiratory Syndrome (SARS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 7 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourcedfrom the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Severe Acute Respiratory Syndrome (SARS) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3-V Biosciences Inc
  • Biotron Ltd
  • CEL-SCI Corp
  • GeneCure LLC
  • Gilead Sciences Inc
  • Novavax Inc
  • MORE
Introduction

The Publisher's Report Coverage

Severe Acute Respiratory Syndrome (SARS) - Overview

Severe Acute Respiratory Syndrome (SARS) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Severe Acute Respiratory Syndrome (SARS) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Severe Acute Respiratory Syndrome (SARS) - Companies Involved in Therapeutics Development

3-V Biosciences Inc

Autoimmune Technologies LLC

Biotron Ltd

CEL-SCI Corp

GeneCure LLC

Gilead Sciences Inc

Novavax Inc

Oncovir Inc

Phelix Therapeutics LLC

Sanofi

Severe Acute Respiratory Syndrome (SARS) - Drug Profiles

CEL-1000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSW-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

D-3252 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Inhibit Cathepsin L for Coronaviridae Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-5734 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ML-188 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for SARS Virus Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Poly-ICLC - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SARS (virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

severe acute respiratory syndrome vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Coronavirus Infection, Ebolavirus Infections and Severe Acute Respiratory Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SSYA-10001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TVB-3567 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Severe Acute Respiratory Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Severe Acute Respiratory Syndrome (SARS) - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Severe Acute Respiratory Syndrome (SARS) - Pipeline by 3-V Biosciences Inc, H1 2018

Severe Acute Respiratory Syndrome (SARS) - Pipeline by Autoimmune Technologies LLC, H1 2018

Severe Acute Respiratory Syndrome (SARS) - Pipeline by Biotron Ltd, H1 2018

Severe Acute Respiratory Syndrome (SARS) - Pipeline by CEL-SCI Corp, H1 2018

Severe Acute Respiratory Syndrome (SARS) - Pipeline by GeneCure LLC, H1 2018

Severe Acute Respiratory Syndrome (SARS) - Pipeline by Gilead Sciences Inc, H1 2018

Severe Acute Respiratory Syndrome (SARS) - Pipeline by Novavax Inc, H1 2018

Severe Acute Respiratory Syndrome (SARS) - Pipeline by Oncovir Inc, H1 2018

Severe Acute Respiratory Syndrome (SARS) - Pipeline by Phelix Therapeutics LLC, H1 2018

Severe Acute Respiratory Syndrome (SARS) - Pipeline by Sanofi, H1 2018

Severe Acute Respiratory Syndrome (SARS) - Dormant Projects, H1 2018

Severe Acute Respiratory Syndrome (SARS) - Dormant Projects, H1 2018 (Contd..1), H1 2018

List of Figures

Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 3-V Biosciences Inc
  • Autoimmune Technologies LLC
  • Biotron Ltd
  • CEL-SCI Corp
  • GeneCure LLC
  • Gilead Sciences Inc
  • Novavax Inc
  • Oncovir Inc
  • Phelix Therapeutics LLC
  • Sanofi
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll